2 active not recruiting, 1 completed, 1 recruiting. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 2, Completed 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Squamous Cell Carcinoma of Unknown Primary: new trials by email Literature Review of Squamous Cell Carcinoma of Unknown Primary trials Research Report on Squamous Cell Carcinoma of Unknown Primary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | Emory University | 40 | 2025-05-08 | 2026-03-04 |
| Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Carboplatin, Cemiplimab, Paclitaxel - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Marcelo Bonomi | 46 | 2021-11-30 | 2026-06-25 |
| Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Cetuximab, Durvalumab, Intensity-Modulated Radiation Therapy - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 196 | 2018-04-03 | 2026-08-27 |
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 68 | 2017-09-27 | 2026-08-13 |
Hypopharyngeal Neoplasms (3) · Laryngeal Neoplasms (3) · Mouth Neoplasms (3) · Oropharyngeal Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Carcinoma (2) · Adenocarcinoma, Papillary (1) · Carcinoma, Basal Cell (1) · Carcinoma, Basosquamous (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Signet Ring Cell (1) · Eccrine Porocarcinoma (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1)
Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Neoplasms, Glandular and Epithelial (4) · Carcinoma, Squamous Cell (3) · Head and Neck Neoplasms (3) · Laryngeal Diseases (3) · Mouth Diseases (3) · Otorhinolaryngologic Diseases (3) · Otorhinolaryngologic Neoplasms (3) · Pharyngeal Diseases (3) · Pharyngeal Neoplasms (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Stomatognathic Diseases (3)
Specimen Handling (2) · (225)Ac-DOTA-c(RGDyK) (1) · Biopsy (1) · Carboplatin (1) · Cetuximab (1) · Disulfides (1) · Immunoglobulin G (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Paclitaxel (1) · Radiotherapy, Intensity-Modulated (1) · Surgical Procedures, Operative (1) · Taxes (1) · cemiplimab (1) · durvalumab (1)
National Cancer Institute (NCI) (2) · Emory University (1) · Marcelo Bonomi (1)
United States (4) · Canada (1)
Dong M. Shin, MD, FACP, FAAAS (1) · Loren K Mell (1) · Marcelo R Bonomi, MD (1)
P30CA138292 (1), R01CA262123 (1), U10CA180868 (1), UM1CA186709 (1), UM1CA186716 (1)